Cost-Based Reimbursement, Infusion Capacity, and a 340B Proposal at a Critical Access Hospital
Valley Ridge is a 25-bed critical access hospital whose Medicare outpatient services are paid at 101% of reasonable cost. Its infusion center has six chairs and completed 3,200 visits last year at an average drug-and-supply cost of $1,340 and variable nursing cost of $180 per visit. Payer mix is 62% Medicare, 30% commercial (average all-in payment $2,480 per visit), and 8% Medicaid (92% of cost). Chair occupancy reaches 91% between 9 a.m. and 2 p.m., and 180 patients were rescheduled or diverted last quarter. Administration proposes four additional chairs ($180,000) and 2.0 FTE RNs ($190,000 loaded) to absorb 900 more visits a year, with an incremental mix of 70% Medicare, 25% commercial, and 5% Medicaid. Separately, the pharmacy director proposes a 340B contract-pharmacy arrangement; annual drug spend is $4.2M. The CFO wants a recommendation before the October board meeting. The hospital's Medicare cost report is settled roughly two years in arrears.
1. Should the board approve the four-chair expansion? Show the incremental economics by payer, state what the decision actually depends on, and identify the sensitivity that could reverse your answer.
Read the worked answer
Step 1 - Build the fully allocated cost per incremental visit.
- Variable cost: $1,340 + $180 = $1,520
- Added fixed cost spread over 900 visits: $370,000 / 900 = $411
- Fully allocated cost: $1,931
Step 2 - Margin by payer.
| Payer | Visits | Payment | Margin/visit | Total |
|---|---|---|---|---|
| Medicare (101% of cost) | 630 | $1,950 | +$19 | +$12,200 |
| Commercial | 225 | $2,480 | +$549 | +$123,500 |
| Medicaid (92% of cost) | 45 | $1,777 | −$154 | −$6,950 |
| Net | 900 | ≈ $128,700 |
Payback on $370,000 is about 2.9 years; on a pure cash-contribution basis (ignoring the added fixed cost) it is under 18 months.
Step 3 - What the decision depends on. Roughly 96% of the net margin comes from 225 commercial visits, while 70% of the volume is economically neutral because payment tracks cost almost exactly. This is a commercial-volume bet, not a volume bet. Before committing capital, test whether the 9 a.m.–2 p.m. constraint is really a chair problem: 180 diverted patients last quarter may reflect scheduling templates, not physical capacity. Spreading appointments could recover visits at near-zero capital cost.
Step 4 - Reversal sensitivity. Medicare's 101% applies only to allowable cost. If $100,000 of the new RN and depreciation expense is disallowed or deferred in the cost report, Medicare revenue falls by roughly 630/900 × $100,000 × 1.01 ≈ $70,700, cutting net margin to about $58,000 and stretching payback past six years. Also confirm that growth does not threaten the 25-bed limit or the 96-hour average length of stay, since losing CAH status would reprice the entire hospital, not just this department.
2. The pharmacy director projects that 340B will save roughly 30% of the $4.2M drug spend, or about $1.26M. Where do those dollars actually land at a cost-based hospital, and what would you recommend?
Read the worked answer
Where the discount lands, by payer.
- Medicare (62% of spend, $2.60M): essentially nowhere. Under cost-based reimbursement the drug is both reimbursed and reported at actual cost. A 30% acquisition discount lowers the reported cost and therefore lowers the payment by nearly the same amount; the retained benefit is roughly the 1% margin, on the order of $8,000. The $781,000 of "savings" here is largely an illusion in a CAH.
- Commercial (30%, $1.26M): the real prize. Commercial contracts pay a fixed all-in rate of about $2,480 per visit regardless of acquisition cost, so the discount drops straight to margin. At a 30% discount that is about $378,000 before fees.
- Medicaid (8%, $336,000): partial. At 92% of cost the hospital retains roughly 8 cents on each discounted dollar, about $27,000, and duplicate-discount rules apply (carve out Medicaid or bill with 340B modifiers and use the correct NDC).
- Self-pay/uninsured: full benefit.
Realistic annual value is roughly $365,000 net of contract-pharmacy fees, one quarter of the projection.
Recommendation. Approve a scoped arrangement, not a broad one: model by payer and by NDC first; register the smallest compliant pharmacy network; require claim-level NDC tracking, patient-definition documentation, and audit rights in the pharmacy agreement; and report capture rate monthly. Because the CAH's economics do not reward 340B on Medicare, the business case must be underwritten by commercial volume - which is the same volume the chair expansion depends on. Both decisions rise or fall together.
3. Name the four or five measures you would put on a one-page board dashboard to govern both decisions after approval, and explain why each one is diagnostic rather than decorative.
Read the worked answer
- Net revenue per completed visit, split by payer (monthly). The whole business case depends on the commercial share of incremental volume. If incremental commercial visits fall below roughly 20% of new volume, the payback story breaks. Reporting only aggregate margin hides this.
- Chair utilization by hour of day, plus diverted/rescheduled counts. Overall utilization is a misleading average when the constraint is 9 a.m.–2 p.m. Hourly utilization tells the board whether the fourth chair was needed or whether scheduling templates were the fix.
- Cost report settlement variance: interim payments versus filed cost, tracked quarterly. Because settlement lags two years, Medicare "profit" is an estimate. A rolling variance track record tells the board whether the 101% assumption is holding in practice, and flags disallowed costs early enough to correct documentation.
- 340B capture rate and discount dollars by payer. Report gross discount, fees, and net retained dollars separately by Medicare, commercial, Medicaid, and self-pay. A single blended savings number would obscure that most of the Medicare discount is passed back.
- CAH status tripwires: inpatient beds staffed, average length of stay, discharges, and distance/necessity attestation dates. These are the conditions that keep the cost-based model alive; a single quarter over the bed limit is an existential risk, not an operational one.
Add a review trigger: if commercial mix on new visits drops below 20% for two consecutive quarters, or if the first cost report shows more than $75,000 of disallowed incremental cost, the board should revisit the second phase of the expansion.